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ABSTRACT: This study was performed to determine the efficacy of orally administered oxolinic acid 
and Vetoquinol, an oxolinic acid ester, in the treatment of experimental induced furunculosis in 
Atlantic salmon Salmo salar held in seawater. Two strains of the causative bacterium Aeromonas 
salmonjcida subsp. salmonicida, 1 sensitive (VI-88/09/031?5) and 1 resistant (3475/90) to oxolinic acid, 
were used. In 2 trials, cohabitational challenges were performed by ~ntroducing 8 fish challenged in 
advance by an intraperitoneal injection of 2.2 X 104 colony forming units of strain 34?5/90 (Trial 1) or 
strain VI-88/09/031?5 (Trial 2) to 10 aquaria each containing 40 healthy fish. The treatment groups in 
both trials consisted of 4 groups receiving either oxolinic acid (2 groups) or Vetoquinol (2 groups) and 
1 control group. An unchallenged, unmedicated group was used to determine the natural mortality in 
the population. The recommended therapeutic dose of 25 mg oxolinic acid kg-' f ~ s h  at Days 1, 2 ,  4 ,  6, 8 
and 10 following initiation of treatment was used. Oral medication initiated at Day 10 (Trial 1) or Day 
11 (Trial 2) following challenge significantly (p < 0.05) lowered the specific mortality in all drug-treated 
groups compared to the untreated control groups. Mortality in Vetoquinol-treated groups was signifi- 
cantly (p < 0.05) lower than in oxolinic acid-treated groups in Trial 1 whereas no significant (p < 0.05) 
difference in survival rate was found between the medicated groups in Trial 2. 
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INTRODUCTION 
Vaccination and improved management practices 
have reduced the problem with bacterial diseases in 
the culture of Atlantic salmon Salmo salar in Norway. 
However, when outbreaks occur, antimicrobial ther- 
apy is essential to treat the infection. The quinolones 
flumequine and oxolinic acid have been shown to be 
effective against a number of bacterial infections in 
fish (Michel et al. 1980, Austin et al. 1983, Rodgers & 
Austin 1983, Scallan & Smith 1985, O'Crady et al. 
1988) and have since their introduction in 1987 (oxo- 
linic acid) and 1989 (flumequine) been the drugs of 
choice in Norwegian aquaculture (Grave et al. 1996). 
Quinolones are broad-spectrum synthetic antibacterial 
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agents especially active against Gram-negative bacte- 
ria. The antibacterial activity is based on the inhibition 
of DNA-gyrase, resulting in an unstable condensation 
of the DNA configuration of the bacterial DNA mole- 
cule during cell division (Wolfson & Hooper 1989). 
Extensive use of an antibacterial agent may cause 
the emergence of bacterial strains resistant to a drug 
and thereby decrease the efficacy of treatment. 
Tsoumas et al. (1989) suggested that a bacterium 
should be considered susceptible to oxolinic acid if the 
in vitro minimum inhibitory concentration (MIC) is 
<0.0625 pg ml-' and moderately susceptible when the 
MIC is within the range of 0.125 to 0.5 pg ml-l. With an 
MIC of 21.0 1-19 ml-' a strain should be classified as 
resistant. Barnes et al. (1990) found the in vitro MIC 
values for oxolinic acid against 45 susceptible strains of 
Aeromonas salmonicida to range from 0.05 to 0.7 pg 
ml-l and from 1 to 15 pg ml-' for 38 resistant strains. Of 
44 tested strains of Aeromonas salmonicida subsp. 
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salmonicida, Martinsen et al. (1992) found 22 strains to 
be oxolinic acid sensitive and 22 strains to be oxolinic 
acid resistant, applying the criteria proposed by 
Tsoumas et  al. (1989). 
A theoretical assessment of the clinical significance 
of an  antibacterial agent towards a specific pathogen is 
based upon pharmacokinetic parameters of the drug 
and the pathogen's MIC value for that particular 
antibacterial. Stamm (1989) has suggested that a peak 
plasma concentration (C,,,):MIC ratio of 4 : l  would be 
sufficient to inhibit bacterial growth whereas Blaser et 
al. (1987), following in vitro studies with the quinolone 
enoxacin, suggested that bacterial regrowth might 
occur unless the ratio achieved was 8 : l .  Furthermore, 
Smith et al. (1994) have argued that any theoretical 
considerations of this issue are complicated by the fact 
that the majority of plasma concentration data has 
been generated by chemical analytical methods like 
high-performance liquid chromatography (HPLC) and, 
therefore, may not express the actual in vivo biological 
activity of the drug. Peak plasma concentrations rang- 
ing from 0.5 to 0.99 pg ml-' are reported for oxolinic 
acid following oral administration of medicated feed at  
a dosage of 25 mg kg-' body weight to Atlantic salmon 
held in seawater (Martinsen 1993, Rogstad et al. 1993, 
Martinsen & Horsberg 1995). Unpublished data by 
Samuelsen (Institute of Marine Research, Bergen. Nor- 
way) showed that oral administration of oxolinic acid 
as the carbitol-ester (Vetoquinol) to Atlantic salmon 
held in seawater enhanced important pharmacokinetic 
properties such as bioavailability, C,,, and T,,, (time 
to reach C,,,) compared to administration of an  equal 
dose of oxolinic acid. A major part of the ester was 
rapidly converted in vivo to oxolinic acid, and the peak 
plasma concentration of oxolinic acid increased from 
0.5 pg ml-' when oxolinic acid was administered to 3.8 
pg  ml-' when Vetoquinol was administered whereas 
T,,, decreased from 19 to 7 h. The gain in pharmaco- 
kinetic properties may improve the efficacy of the drug 
and this study was designed to examine the efficacy of 
orally administrated Vetoquinol and oxolinic acid in 
the treatment of furunculosis in Atlantic salmon held in 
seawater using a cohabitant challenge model. Two dif- 
ferent strains of the pathogen were used, 1 sensitive 
(VI-88/09/03175) and 1 resistant (3475/90) to oxolinic 
acid, following the criteria proposed by Tsoumas et al. 
(1989). 
MATERIALS AND METHODS 
Chemicals. Flumequine, oxolinic acid and metorni- 
date were from Norsk Medisinaldepot (Bergen. Nor- 
way). Vetoquinol, the carbitol ester of oxolinic acid was 
kindly supplied by Prof. Loubinoux (Universite de 
Nancy, France). Methanol, acetonitrile, tetrahydrofu- 
ran (HPLC-grade) and oxalic acid dihydrate, TRIS and 
HC1 (p.a.-grade) were all from Merck (Darmstadt, Ger- 
many). 
Stock solutions of flumequine, oxolinic acid and 
Vetoquinol were prepared at a concentration of 0.1 mg 
ml-' in acetonitrile and stored at -20°C. Acetonitrile 
was used due to de-esterification of Vetoquinol when 
stored in methanol or diluted alkali (0.025 M NaOH). 
Working standards were prepared by dilution from the 
stock solutions with acetonitrile. 
MIC determinations. Determination of MIC values 
was performed using the agar dilution method (Wash- 
ington 1985, Samuelsen & Lunestad 1996) with some 
modifications. Strains were maintained on Mueller 
Hinton agar (Difco) supplemented with 2% NaCl. 
Material from the strains were transferred to 10 m1 
Mueller Hinton broth and incubated for 48 h at 20°C 
giving a final cell density of approximately 5 X 108 cells 
ml-l. Using a 10 p1 inoculation loop, bacteria from this 
broth were distributed on the surface of Mueller Hin- 
ton Agar supplemented with 2 % NaCl and containing 
oxolinic acid. The antibacterial agent was added to the 
agar in 2-fold dilutions from a newly prepared stock 
solution. The temperature of the agar on addition of 
the agent was 50°C. Following incubation at  20°C for 
72 h the plates were examined for bacterial growth. 
The lowest concentration of oxolinic acid at  which 
complete inhibition occurred was recorded as the MIC. 
MIC testing was performed in triplicate. 
Feed. Both medicated and non-medicated feeds for 
oral administrations were made at the Institute of 
Nutrition, Directorate of Fisheries (Bergen, Norway). 
The ingredients were squid (9.2 %), wheat meal (17 %), 
herring meal (57%), vitamins and minerals (1.8%), 
gelatin (3%) and herring oil (12%). The medicated 
feeds were made by homogeneously mixing 5 g 
oxolinic acid or 7.2 g Vetoquinol, corresponding to 
19.2 mm01 for both compounds, with 1 kg fish feed 
ingredients. 
Experimental fish. Non-vaccinated Atlantic salmon 
with a mean weight of 65 * 9 g were ~naintained in a 
circular (1 m X 2.5 m inside diameter) flow-through 
seawater storage-tank at the laboratory of the Institute 
of Marine Research, Bergen, Norway. The seawater 
had a salinity of 33% and a temperature of 11.5 t 
0.5"C. The fish were fed a non-medicated ration of 1 % 
body weight d-l of dry pellets. 
Challenge. Aeromonas salmonicida subsp. salmoni- 
cida strain VI-88/09/03175 (Culture collection, Central 
Veterinary Laboratory, Oslo, Norway) and strain 
3475/90 (Norwegian College of Veterinary Medicine, 
Oslo, Norway) were used for the challenge experi- 
ments. These strains are pathogenic to Atlantic 
salmon. With MIC values of 0.13 and 4 pg ml-l, respec- 
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tively, strain VI-88/09/03175 is classified as moderately 
susceptible and strain 3475/90 as resistant to oxolinic 
acid (Tsoumas et al. 1989). The bacteria were stored in 
cryotubes with glycerol at -80°C. Prior to challenge, 
the bacteria were inoculated into brain heart infusion 
broth (BHIB) from Merck and incubated at 20°C. After 
24 h,  1 % of this culture was inoculated into a new cul- 
ture and incubated for 24 h.  The bactei-la were har- 
vested by centrifugation at 4000 rpm (2750 X g) and 
4°C for 10 min and washed twice with 0.85% sterile 
NaCl. The pellet was resuspended to 40% transmis- 
sion reading and diluted to I O - ~  in 0.85 % sterile NaCl 
prior to the injection. The number of colony-forming 
units (CFUs) was determined by plate counts. 
Fish from the storage tank were randomly assigned 
to 10 groups, each of 40 fish and transferred to 10 cir- 
cular (0.8 m X 1 m inside diameter) flow-through sea- 
water tanks maintained at 11.5 * O.S°C. The fish were 
acclimatised for 2 wk. At the end of the acclimatisation 
period the fish consumed the apportioned amount of 
unmedicated feed of 1 % body weight d-'. 
Trial 1: A cohabitation challenge was performed by 
transferring 8 challenged fish to each of 5 tanks 
containing 40 healthy fish. Prior to the transfer the 
cohabitant fish were anaesthetised by immersion in a 
solution of metomidate (5 mg 1-l) in seawater for 
approximately 5 min, marked by fin clipping and chal- 
lenged by an intraperitoneal injection of 2.2 X 104 CFU 
of the bacterial strain 3475/90. This corresponded to a 
challenge pressure of 20% (% cohabitant fish to non- 
cohabitants). Treatment with oxolinic acid (Groups 1 
and 2) and Vetoquinol (Groups 3 and 4) was initiated at 
Day 10 postchallenge with medication at Days 1, 2, 4, 
6, 8 and 10 following initiation of treatment. The fish in 
Group 5 received no medication and served as con- 
trols. 
Trial 2: In Trial 2, 8 cohabitant fish were anaes- 
thetised using metomidate, marked by fin clipping and 
challenged by an intraperitoneal injection of 2.2 X 104 
CFU of the bacterial strain VI-88/09/031?5 prior to 
transfer to each of the 5 remaining tanks. Treatment 
with oxolinic acid (Groups 6 and 7) and Vetoquinol 
(Groups 8 and 9) was initiated at Day 11 postchallenge 
with medication at  Days 1, 2, 4, 6, 8 and 10 following 
initiation of treatment. The fish in Group 10 received 
no medication and served as controls. 
On the day of challenge the seawater temperature in 
all tanks was raised from 11.5 to 14OC and kept at  14 + 
O.S°C for the rest of the experiment. The water flow 
was 4 1 min-' and the oxygen concentration was 8.0 mg 
1-'. 
Treatment. The medicated feeds contained oxolinic 
acid and Vetoquinol at  a concentration of 5 and 7.2 g, 
respectively, kg-' feed, designed to deliver a dosage of 
25 mg oxolinic acid kg-' body weight d-' based on 
administration of a daily feed ration of 0.5 % fish body 
weight. During medication the fish in the control 
groups were fed a ration of unmedicated feed of 0.5 O/U 
fish body weight d-l. The fish were fed once a day and 
approximately 1 h after feeding excess food was col- 
lected from each tank and the percentage of med- 
icated feed consumed each day estimated. The amount 
of feed administered each day was readjusted to 
account for fish that had died in the tanks duiing the 
last 24 h. In the post medication period, the feed and 
feeding regime was as described for the acclirnatisa- 
tion period. The fish in both trials were observed for 
24 d postchallenge and mortality was recorded daily. 
Dead fish were removed from the tanks once a day and 
examined for food residues in the stomach and gut. 
Samples of muscle were obtained from the dead fish 
and stored at  -20°C until analysed for oxolinic acid 
and Vetoquinol residues. Kidney samples from the 
dead fish and 5 surviving fish from each group were 
inoculated on brain heart broth (BHB) (Merck) and 
incubated aerobically at 20°C for 4 d. The Aeromonas 
salmonicida subsp. salmonicida strains were identified 
according to morphology, production of brown pig- 
ment, positive agglutination test (Mono-Va, BioNor 
Aqua, Skien, Norway) and biochemical characteristics 
in API 20 E (bio Merieux, Marcy l'Etoile, France). An 
additional group of 100 unchallenged fish was used to 
determine the natural mortality in the population. 
Treatments were compared on the basis of cumulative 
mortality at the end of the study using the mean value 
of parallel treated groups and the chi-square test. 
Sample preparation. Samples of muscle (1 g) were 
homogenised in 1.0 m1 of a 50:50 O/o solution of acetoni- 
trile and 0.05 M Tris:HCl buffer (pH 8.0) containing 
flumequine as internal standard. Following homogenl- 
sation, 0.5 m1 of the homogenate was transferred to a 
polypropylene tube and kept in the dark at 4OC for 24 h 
for complete precipitation of proteins. Flumequine, 
oxolinic acid and Vetoquinol were all found to be sta- 
ble for 24 h in the solution of acetonitrile and Tris:HCl 
buffer. After centrifugation at  12000 X g in a Biofuge A 
table-centrifuge (Heraeus Sepatech, Osterode am 
Harz, Germany) for 5 min, a clear supernatant was 
obtained, ready for analysis. 
Chromatography. The HPLC system used consisted 
of a Spectra-Physics SP 8800 ternary HPLC pump 
(Spectra-Physics, San Jose, CA, USA) connected to a 
Spectra-Physics SP 8780 X R Autosampler and a Shi- 
madzu RF-535 fluorescence detector (Shimadzu, 
Kyoto, Japan) operating at an  excitation wavelength of 
325 nm and an emission wavelength of 360 nm. The 
integrator was the model SP-4270 from Spectra- 
Physics. The HPLC system was programmed to inject 
20 p1 samples into the 150 X 4.6 mm analytical column 
packed with 3 pm particles of ODS-Hypersil (C-18) 
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(Shandon Southern Products, Astmoor, UK) in our lab- 
oratory using a Shandon column packing machine. 
The column was operated at room temperature. The 
mobile phase used contained A: 0.025 M oxalic acid 
pH 3.2 - acetonitrile - methanol - tetrahydrofuran (70 - 
7.5 - 20 - 2.5 v/v); and B: 0.025 M oxalic acid pH 3.2 - 
acetonitrile - methanol - tetrahydrofuran (50 - 20 - 25 - 
5 v/v). The solutions were filtered through a 0.2 pm 
Millipore filter. The elution profile was as follows: 0 to 
4 min isocratic 100% A; 4.1 to 10 rnin 0 to 100% B lin- 
ear gradient; 10.1 to 15 min isocratic 100% B; 15.1 to 
20 rnin isocratic 100% A. The flow rate was 1 m1 min-l, 
giving elution times of 8.6 min (oxolinic acid), 9.3 rnin 
(Vetoquinol) and 12.8 min (flumequine). 
Muscle samples from 3 fish were taken prior to initi- 
ation of the study and analysed to confirm the absence 
of flumequine, oxolinic acid and Vetoquinol. Standard 
curves for oxolinic acid and Vetoquinol in muscle in 
the range of 0.01 to 1.0 pg g-', using an  internal stan- 
dard concentration of 1.0 pg g-' and 1.0 to 10.0 pg g-' 
(internal standard of 5.0 pg g-l), were prepared in trip- 
licate. Based on the standard curves, the limits of 
quantitation in this investigation were set to 0.025 pg 
g-' for oxolinic acid and 0.1 pg g-' for Vetoquinol in 
muscle samples. 
RESULTS 
Trial 1: Within 7 d after challenge the majority of the 
fish challenged with an intraperitoneal injection of the 
pathogen were dead whereas the first deaths of semi- 
challenged fish occurred at Day 10 following chal- 
lenge. Among challenged controls (Group 5) the 
cumulative mortality reached 92 % during the post- 
challenge period of 24 d.  For fish medicated with 
oxolinic acid the final cumulative mortality was 76 % 
whereas for fish medicated with Vetoquinol a final 
cumulative mortality of 60% was found. Cumulative 
mortalities over time are presented for the medicated 
groups as the mean value of the 2 groups with parallel 
treatment (Fig. 1). No mortality was observed in the 
unchallenged, unmedicated group. Survival of fish 
medicated with oxolinic acid and Vetoquinol were sig- 
nificantly (p  < 0.05 and p c 0.005, respectively) greater 
than suMval of challenged unmedicated fish. The 
mortality of Vetoquinol-treated fish was significantly 
lower (p 0.05) than fish treated with oxolinic acid. A 
companson of mortality in groups with an identical 
treatment regime demonstrated no significant differ- 
ence between the groups (p  > 0.05). The relative per 
cent survival (RPS) (Inglis et al. 1991) was calculated to 
be 18 and 35 % respectively when treated with oxolinic 
acid or Vetoquinol. The mortality ceased withln 8 d in 
all medicated groups after initiation of treatment. 
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Fig. 1. Salmo salar. Cumulative mortalities over time of med- 
icated and nonmedicated groups challenged with an oxolinic 
acid resistant strain of Aeromonas salmonicida subsp. sal- 
monicida (MIC value of 4 pg ml-') in Trial 1. Data is presented 
as mean values of parallel tanks applying original mortality 
data. Oral medication was initiated at Day 10 following 
challenge 
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Fig. 2. Salmo salar. Cumulative mortalities over time of med- 
icated and nonmedicated groups challenged with a sensitive 
strain of Aeromonas salmonicida subsp. salmonicida (MIC 
value of 0.13 pg ml-l) in Trial 2. Data is presented as mean 
values of parallel tanks applying original mortality data. Oral 
medication was initiated at Day 11 following challenge 
Trial 2: When the first deaths of semi-challenged fish 
occurred in Trial 2 at Day 11 following challenge, half 
of the fish challenged with an intraperitoneal injection 
were dead. Among challenged controls (Group 10) the 
mortality reached 75 % during the postchallenge period 
of 24 d. For fish medicated with oxolinic acid a final 
cumulative mortality of 29.5 % was found whereas the 
corresponding value for fish medicated with Vetoquinol 
was 20%. Cumulative mortalities over time (mean 
value of parallel treated groups) are shown in Fig. 2. 
Survival of fish in all medicated groups were signifi- 
cantly (p c 0.005) greater than survival of challenged 
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unmedicated fish. No significant (p  < 0.05) difference in 
survival rate was found between the groups medicated 
with oxolinic acid or Vetoquinol. However, a significant 
difference (p < 0.05) was found between Groups 6 and 
7, medicated with oxolinic acid in a parallel treatment. 
In this trial the RPS values were calculated to be 61 and 
73%, respectively, when treated with oxolinic acid or 
Vetoquinol. The mortality ceased within 4 d in all 
medicated groups after initiation of treatment. 
Aeromonas salmonicida subsp, salmonicida was iso- 
lated from the kidneys from all examined dead fish 
from both trials whereas the pathogen was not isolated 
from the survivors of either of the medicated groups. 
In all tanks throughout the experiment, 100% of the 
ration of medicated feed was consumed. The dead fish, 
classified as low-feeders, had no or very little feed in 
the stomach or intestine. This observation was con- 
firmed by the HPLC analysis showing low concentra- 
tions (c 0.8 pg g-l) of oxolinic acid in muscle of the dead 
fish. In comparison the mean concentration of oxolinic 
acid in muscle of surviving fish from Trial 2 was 2.85 pg 
g-' 5 d following the termination of medication. 
DISCUSSION 
The culture and presumptive identification of 
Aeromonas salmonicida subsp. salmonicida from the 
dead fish from both trials was expected and validates 
the pathogen as the probable cause of death. None of 
the surviving medicated fish cultured positive for A. 
salmonicida subsp. salrnonicida, indicating that the 
pathogen was effectively removed from the fish by the 
antibacterials. 
In this investigation the MICs for oxolinic acid 
against the bacterial strains were 0.13 pg ml-' for strain 
VI-88/09/03175 and 4 pg ml-' for strain 3475/90. These 
results are in accordance with the results of Oppe- 
gaard & Ssrum (1994), who found the MIC value for 
strain 3475/90 to be 2.56 pg ml-l. 
Although oxolinic acid has been used to treat furun- 
culosis in Atlantic salmon for years, surprisingly few 
data on the in vivo efficacy of this antibacterial agent 
against infection with Aeromonas salmonicida are 
available. In this investigation we found the cumula- 
tive mortality in the groups medicated with oxolinic 
acid or Vetoquinol in both trials to be significantly (p < 
0.05 and p < 0.005) lower compared to unmedicated 
groups. The efficacy of a medical treatment can be 
expressed by calculation of the RPS value. This calcu- 
lation allows the effect of treatment to be measured 
against the severity of challenge. In the present study a 
total dose of 150 mg orally administered oxolinic acid 
kg-' body weight gave a RPS value of 18% in Trial 1 
and 61 % in Trial 2 whereas oral administration of 
Vetoquinol gave RPS values of 35 and 73%, respec- 
tively. For Trial 2 our findings are similar to previously 
published results. From data presented by Nordmo et 
al. (1998) a RPS value of 56.4 'X0 could be calculated for 
oxolinic acid in treating furunculosis-infected Atlantic 
salmon with a daily dose of 25 mg kg-' fish d-' for 10 d. 
Daily medication with flumequine (25 mg kg-'), oxyte- 
tracycline (100 mg kg-'), trimethoprim + sulphadiazine 
(5 + 25 mg kg-') and florfenicol ( l 0  mg kg-l) for 10 suc- 
cessive days gave RPS values of 64, 66, 56 and 70%, 
respectively (Nordmo et al. 1998). Initiating medica- 
tion at Days 10, 13 and 16 following a cohabitational 
challenge of Atlantic salmon held in seawater with A. 
salmonicida subsp. salmonicida, daily doses of florfeni- 
col (10 mg kg-') for 10 d gave RPS values of 96, 84 and 
76%, respectively (Samuelsen et al. 1997), whereas 
Inglis et  al. (1991) found a RPS value of 82% when 
treating furunculosis-infected Atlantic salmon parr 
with florfenicol. Field trials for the treatment of furun- 
culosis-infected rainbow trout with oxolinic acid 
yielded 99 % survival in the treated group versus 69 % 
survival in the unmedicated group giving a RPS value 
of 97 % (Austin et al. 1983). It must be noted, however, 
that due to variables in experimental set-up and test 
systems between the different investigations compar- 
isons of RPS values must be made with caution. 
Statistical treatment of our data suggest that medica- 
tion with Vetoquinol was superior to medication with 
oxolinic acid in Trial 1 and that, although a trend in 
increasing efficacy using Vetoquinol compared to 
oxolinic acid was observed in Trial 2, the difference 
between the groups was not large enough to be statis- 
tically significant, at  least at  the sample size employed 
in this study. It is of interest that even though an  
oxolinic acid-resistant strain was used in Trial 1, treat- 
ment with oxolinic acid gives at least some protection 
against the pathogen since the final cumulative mor- 
tality using oxolinic acid was found to be significantly 
(p < 0.05) lower compared with the control group. It 
must be kept in mind, however, that oxolinic acid resis- 
tant isolates of Aeromonas salmonicida with MIC val- 
ues much higher than 4 pg ml-' are described in the lit- 
erature and that medication even with Vetoquinol 
most probably would be inappropriate for the treat- 
ment of such isolates (Barnes e t  al. 1990, Martinsen et  
al. 1992). Figs. 1 & 2 show that the major difference in 
mortality rate between the 2 drugs is in the first 3 d fol- 
lowing initiation of treatment where the mortality is 
nearly twice as large in the oxolinic acid-treated 
groups compared to the Vetoquinol groups. This 
observation is supported by unpublished data of 
Samuelsen, who found that important pharmaco- 
kinetic parameters such as bioavailability, C,,, and 
T,,, were largely improved when Vetoquinol was 
administered as compared to oxolinic acid. Our data 
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validate the importance of obtaining a high concentra- 
tion of the antibacterial in the fish as quickly as possi- 
ble and suggest that the efficacy of a high loading dose 
of the antibacterial agent at Day 1 of medication should 
be investigated. 
To test the efficacy of chemotherapeutants, different 
challenge models have been used to experimentally 
induce furunculosis in fish (Elston et al. 1995, 
Samuelsen et  al. 1997, Nordmo et al. 1998). To mimic 
natural infection the disease was induced in this inves- 
tigation by introduction of cohabitant fish previously 
infected by an  intraperitoneal injection with the 
pathogen. However, as previously shown by Nordmo 
et al. (1998), it is more difficult to achieve an identical 
challenge environment in all tanks in a cohabitant 
challenge model compared to intraperitoneal inocula- 
tion. In Trial 2 in this study we found a significant (p 
0.05) difference in final cumulative mortality between 
the 2 parallel tanks treated with oxolinic acid (Groups 
6 and 7). However, in Group 7 the premedication mor- 
tality among the semi-challenged fish was higher than 
in the other groups. If this effect was adjusted for by 
reducing the number of fish in Group 7 to a premed- 
ication mortality corresponding to the mean value of 
the 4 remaining groups, no significant (p < 0.05) differ- 
ence was then found between Groups 6 and ?. It 
should be noted that the figures and the statistical cal- 
culations presented in this investigation were based 
upon the original data. However, the results of the sta- 
tistical calculations were not altered if the adjusted 
data were used. 
The feeding observations made in these trails ven- 
fied that all the medicated feed was consumed by the 
fish. However, the dead fish had no or very little feed in 
the intestine and were classified as low-feeders. This 
observation was confirmed by the HPLC analysis 
showing the absence or low concentrations (<0.8 pg 
g-') of oxolinic acid in muscle of the dead fish. In com- 
parison, the mean concentration of oxolinic acid in 
muscle of 20 surviving fish from Trial 2 were 2.85 pg 
g-', 5 d following terminated medication. We therefore 
believe that most of the fish not consuming the full 
dose may have been the individuals succumbing to the 
disease. 
These studies indicate that the value of Vetoquinol in 
treating furunculosis in Atlantic salmon held in sea- 
water lies in its better effect on bacterial strains classi- 
fied as resistant, as shown in Trial 1, and the quicker 
response (i.e. lower mortality rate) in the first days of 
treatment compared to oxolinic acid, as shown in both 
trials in this investigation. 
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